South San Francisco, CA-based ORIC Pharmaceuticals has named Ashraf Hanna its CEO, replacing Rich Heyman, who helped ORIC raise a $53 million Series B in December while filling the role on an interim basis. Hanna was previously a commercial and medical affairs executive at Genentech, as well as the CFO of the Genentech Foundation. Heyman is remaining on the company’s board. ORIC also hired Darcy Mootz, the former vice president of corporate development at Achaogen, as its chief business officer.
Author: David Holley
David is the national correspondent at Xconomy. He has spent most of his career covering business of every kind, from breweries in Oregon to investment banks in New York. A native of the Pacific Northwest, David started his career reporting at weekly and daily newspapers, covering murder trials, city council meetings, the expanding startup tech industry in the region, and everything between. He left the West Coast to pursue business journalism in New York, first writing about biotech and then private equity at The Deal. After a stint at Bloomberg News writing about high-yield bonds and leveraged loans, David relocated from New York to Austin, TX.
He graduated from Portland State University.
View all posts by David Holley
